Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data

Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, is indicated by the US FDA for the treatment of patients with CLL/small lymphocytic lymphoma, and allows for treatment without chemotherapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research